Drug Type NK-TCR cells |
Synonyms- |
Target |
Action agonists, inhibitors |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), IL15R agonists(Interleukin-15 receptors agonists), NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Preclinical | United States | 20 Apr 2026 | |
| Melanoma | Preclinical | United States | 20 Apr 2026 | |
| Multiple Myeloma | Preclinical | United States | 20 Apr 2026 | |
| Synovial Sarcoma | Preclinical | United States | 20 Apr 2026 |





